Anticholinergic burden for prediction of cognitive decline or neuropsychiatric symptoms in older adults with mild cognitive impairment or dementia (Protocol)

Martin Taylor-Rowan, Olga Kraia, Christina Kolliopoulou, Amanda J. Cross, Carrie Stewart, Phyo K. Myint, Jenny McCleery, Terry J. Quinn

Research output: Contribution to journalArticleResearchpeer-review

7 Citations (Scopus)

Abstract

Objectives: This is a protocol for a Cochrane Review (prognosis). The objectives are as follows:. Primary objective. To assess whether anticholinergic burden, as defined at the level of each individual scale, is a prognostic factor for further cognitive decline or neuropsychiatric disturbances in people with mild cognitive impairment (MCI) or dementia. Secondary objective. To compare the prognostic validity of different anticholinergic burden scales. To examine the effect of type of dementia and severity of dementia on the association between anticholinergic burden and rate of cognitive decline or neuropsychiatric disturbances. To examine the effect of setting (care home versus non-care home) on the association between anticholinergic burden and rate of cognitive decline or neuropsychiatric disturbances. To examine whether anticholinergic burden is a prognostic factor for other clinical outcomes in people with MCI or dementia.

Original languageEnglish
Article numberCD015196
Number of pages19
JournalCochrane Database of Systematic Reviews
Volume2021
Issue number11
DOIs
Publication statusPublished - 18 Nov 2021

Cite this